JP3155009B2 - イミダゾール誘導体 - Google Patents

イミダゾール誘導体

Info

Publication number
JP3155009B2
JP3155009B2 JP51159896A JP51159896A JP3155009B2 JP 3155009 B2 JP3155009 B2 JP 3155009B2 JP 51159896 A JP51159896 A JP 51159896A JP 51159896 A JP51159896 A JP 51159896A JP 3155009 B2 JP3155009 B2 JP 3155009B2
Authority
JP
Japan
Prior art keywords
isopropyl
imidazole
ylmethyl
pyridin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51159896A
Other languages
English (en)
Japanese (ja)
Inventor
裕彦 杉本
民雄 藤原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of JP3155009B2 publication Critical patent/JP3155009B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
JP51159896A 1994-09-26 1995-09-25 イミダゾール誘導体 Expired - Fee Related JP3155009B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP25749094 1994-09-26
JP8469095 1995-03-15
JP6-257490 1995-08-12
JP22720595 1995-08-12
JP7-227205 1995-08-12
JP7-84690 1995-08-12
PCT/JP1995/001936 WO1996010019A1 (fr) 1994-09-26 1995-09-25 Derive imidazole

Publications (1)

Publication Number Publication Date
JP3155009B2 true JP3155009B2 (ja) 2001-04-09

Family

ID=27304632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51159896A Expired - Fee Related JP3155009B2 (ja) 1994-09-26 1995-09-25 イミダゾール誘導体

Country Status (20)

Country Link
US (2) US5910506A (zh)
EP (1) EP0786455B1 (zh)
JP (1) JP3155009B2 (zh)
KR (1) KR100387157B1 (zh)
CN (1) CN1093535C (zh)
AT (1) ATE255564T1 (zh)
BR (1) BR9509024A (zh)
CA (1) CA2200316C (zh)
DE (1) DE69532245T2 (zh)
DK (1) DK0786455T3 (zh)
ES (1) ES2211917T3 (zh)
FI (1) FI971234A (zh)
HU (1) HUT77357A (zh)
MX (1) MX9702030A (zh)
NO (1) NO308739B1 (zh)
PL (1) PL183931B1 (zh)
PT (1) PT786455E (zh)
RU (1) RU2157368C2 (zh)
TW (1) TW401404B (zh)
WO (1) WO1996010019A1 (zh)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1940897A (en) * 1996-03-28 1997-10-17 Shionogi & Co., Ltd. Lymph-absorbable imidazole derivatives
JP3272369B2 (ja) * 1996-04-04 2002-04-08 塩野義製薬株式会社 イミダゾール誘導体を含有する抗ｈｉｖ組成物
WO1998029394A1 (fr) * 1996-12-26 1998-07-09 Shionogi & Co., Ltd. Procede de preparation de derives d'imidazole carbamoyles
EP0949249B1 (en) * 1996-12-26 2005-07-13 Shionogi & Co., Ltd. Process for producing imidazole derivatives
TWI232214B (en) * 1998-04-16 2005-05-11 Shionogi & Co Preparation of aryl sulfenyl halide
US6858230B1 (en) 1999-04-12 2005-02-22 Shionogi & Co., Ltd. Process for producing medicinal composition of basic hydrophobic medicinal compound
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
RU2256657C2 (ru) 2001-01-31 2005-07-20 Уорнер-Ламберт Компани Ллс Способ карбамоилирования спиртов
ES2376998T3 (es) * 2001-02-23 2012-03-21 K.U. Leuven Research And Development Derivados de N-aminoimidazol inhibidores de HIV
WO2002085860A1 (en) 2001-04-10 2002-10-31 Pfizer Limited Pyrazole derivatives for treating hiv
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
WO2003091264A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
JP4485520B2 (ja) 2003-03-24 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
EA200501676A1 (ru) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
WO2005016912A1 (en) * 2003-08-19 2005-02-24 Pfizer Inc. An efficient microbial preparation of capravirine metabolites m4 and m5
EP1678322A2 (en) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
JP2007515495A (ja) 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
WO2005100322A1 (en) * 2004-04-14 2005-10-27 Pfizer Limited Sulphur-linked imidazole compounds for the treament of hiv
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
EP1838679A1 (en) * 2005-01-06 2007-10-03 Pfizer Limited Imidazole derivatives as enzyme reverse transcriptase modulators
ES2538714T3 (es) * 2005-12-01 2015-06-23 F. Hoffmann-La Roche Ag Derivados de 2,4,5-trifenil-imidazolina como inhibidores de la interacción entre las proteínas p53 y MDM2 para el uso en calidad de agentes anticancerosos
CN101415691B (zh) 2006-02-03 2011-12-14 大正制药株式会社 ***衍生物
US7994204B2 (en) 2006-02-06 2011-08-09 Taisho Pharmaceutical Co., Ltd Binding inhibitor of sphingosine-1-phosphate
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
CN101501002B (zh) 2006-08-16 2012-06-27 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
PL2177512T3 (pl) 2007-08-01 2012-09-28 Taisho Pharmaceutical Co Ltd Inhibitor wiązania S1P1
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
CL2008002834A1 (es) * 2007-09-28 2009-09-11 Takeda Pharmaceuticals Co Compuestos heterociclicos de 5 miembros, composicion farmaceutica, util para el tratamiento de la ulcera peptidica, sindrome de zollinger-ellison, gastritis, esofagitis por reflujo, enfermedad sintomatica por reflujo gastroesofagico, esofago de barrett, cancer gastrico, hiperacidez gastrica o ulcera debido a estres posquirurgico.
KR101610415B1 (ko) 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
TW201040168A (en) * 2009-02-12 2010-11-16 Exelixis Inc TGR5 agonists
NZ595890A (en) 2009-03-26 2013-09-27 Takeda Pharmaceutical Pyrazole compound
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2667056T3 (es) * 2012-07-24 2018-05-09 Bial-Portela & Ca, S.A. Compuestos de urea y su uso como inhibidores enzimáticos
EP2716639A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2716632A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
EP3381905A1 (en) * 2017-03-30 2018-10-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Novel antiviral compounds
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150266A (ja) * 1986-12-12 1988-06-22 Mitsui Petrochem Ind Ltd ベンジルイミダゾ−ル誘導体
JPH0283373A (ja) * 1988-05-19 1990-03-23 Nippon Soda Co Ltd ５員環の複素環化合物及びその製造方法
IL98319A (en) * 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
TW235963B (zh) * 1992-01-16 1994-12-11 Shionogi & Co
DE10230797C2 (de) * 2001-07-16 2003-09-25 Dieter Reif Befestigungsklammer zur Verbindung von Holzbauteilen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｊ．Ｃｈｅｍ．Ｓｏｃ．Ｐｅｒｋｉｎ ▲Ｉ▼；（１９７２）Ｎｏ．１５ ｐ１９６０−１９６３
Ｊ．Ｃｈｅｍ．Ｓｏｃ．Ｐｅｒｋｉｎ ▲Ｉ▼；（１９７２）Ｎｏ．１５ ｐ１９９５−１９６０

Also Published As

Publication number Publication date
US6147097A (en) 2000-11-14
DK0786455T3 (da) 2004-03-29
PL320009A1 (en) 1997-09-01
CA2200316A1 (en) 1996-04-04
DE69532245T2 (de) 2004-09-16
CN1093535C (zh) 2002-10-30
BR9509024A (pt) 1997-09-30
NO971306D0 (no) 1997-03-20
FI971234A (fi) 1997-05-23
ES2211917T3 (es) 2004-07-16
EP0786455A4 (en) 1998-12-30
MX9702030A (es) 1997-06-28
NO308739B1 (no) 2000-10-23
AU706095B2 (en) 1999-06-10
EP0786455A1 (en) 1997-07-30
NO971306L (no) 1997-05-21
CA2200316C (en) 2004-09-21
ATE255564T1 (de) 2003-12-15
KR970706260A (ko) 1997-11-03
HUT77357A (hu) 1998-03-30
DE69532245D1 (en) 2004-01-15
RU2157368C2 (ru) 2000-10-10
AU4788896A (en) 1996-04-19
US5910506A (en) 1999-06-08
PT786455E (pt) 2004-02-27
FI971234A0 (fi) 1997-03-25
WO1996010019A1 (fr) 1996-04-04
TW401404B (en) 2000-08-11
CN1158609A (zh) 1997-09-03
PL183931B1 (pl) 2002-08-30
KR100387157B1 (ko) 2003-09-29
EP0786455B1 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
JP3155009B2 (ja) イミダゾール誘導体
AU2001234128B2 (en) Novel imidazoline compounds
JP3930560B2 (ja) 炎症の処置のための１，２−置換イミダゾリル化合物
JP3193706B2 (ja) アミド誘導体又はその塩
JP2000503304A (ja) 新規シクロアルキル置換イミダゾール
JP2000503303A (ja) 新規置換イミダゾール化合物
JP2002509537A (ja) 新規なシクロアルキル置換イミダゾール化合物
JP2002507993A (ja) 新規な置換イミダゾール化合物
WO2007061360A2 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
NO841106L (no) Fremgangsmaate for fremstilling av kondenserte imidazolderivater
JP3004728B2 (ja) 神経伝達物質放出増強薬としての新規な非環式および環式アミド類
CZ20012338A3 (cs) Imidazolové sloučeniny
JP3464498B2 (ja) 抗ｈｉｖ活性イミダゾール誘導体
FI90869B (fi) Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
JP2000503987A (ja) 炎症処置用の異項環置換イミダゾール
HU196989B (en) Process for producing quinoline derivatives and pharmaceuticals comprising same
KR100429754B1 (ko) 이미다졸 화합물 및 아데노신 데아미나아제 억제제로서의그의 용도
KR100481137B1 (ko) 1-치환 4-시아노-1,2,3-트리아졸의 제조방법
SK8232003A3 (en) Farnesyltransferase inhibitors
JPH11513704A (ja) 酸性ピラゾールの新誘導体、それらの製造方法、それらの薬剤としての用途、それらの新規な用途並びにそれらを含有する製薬組成物
JP2003048875A (ja) １，２−エタンジアミン誘導体の製造法
JP2585497B2 (ja) アンジオテンシン２拮抗性ピリジン誘導体
JPH05194429A (ja) アゾール化合物、その製造法および用途

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees